{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}],"title":"None"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}],"title":"Grade 1"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}],"title":"Grade 2"},{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"15"}],"title":"Grade 3"},{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"}],"title":"Grade 4"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Grade 5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"Common Terminology Criteria for Adverse Events (version 4.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. Adverse events reported as definitely, probably, or possibly related to protocol treatment are considered to be related to treatment.","groups":[{"description":"Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 3-5 weeks later by two 28-day cycles of cytarabine.","id":"OG000","title":"Chemotherapy"},{"description":"Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 2-5 weeks later by 3 weeks of low-dose whole-brain radiotherapy (WBRT), followed 3-5 weeks later by two 28-day cycles of cytarabine.","id":"OG001","title":"Chemotherapy + Low-Dose WBRT"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible participants who started protocol treatment","reportingStatus":"POSTED","timeFrame":"At the end of each chemotherapy 28-day cycle, then every 2 months for two years starting 4 weeks after treatment, then every 6 months for 3 years, then yearly. Maximum follow-up at time of analysis was 7.3 years.","title":"Distribution of Participants by Highest Grade Adverse Event Related to Protocol Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}